Conclusions
Sak, a profibrinolytic agent produced by S. aureus that is now readily available by recombinant DNA technology, induces efficient and rapid recanalization in patients with occlusive arterial thrombosis. Its fibrin specificity at clinically effective doses by far exceeds that of any commercially available plasminogen activator. Likewise, the speed and rate of clot lysis compare favorably with established agents, but definition of the relative benefits, especially in terms of reduction of mortality and morbidity, awaits larger comparative trials. The optimal dose and rate of infusion in patients with coronary and peripheral arterial thrombosis, as well as the value of Sak in other thromboembolic disorders (comprising deep venous thrombosis, pulmonary embolism, and ischemic stroke), remain to be established. Notwithstanding its short circulatory half-life, bolus thrombolysis with Sak appears to be feasible. The antigenicity of wild-type Sak argues against repeated administration, but limited experience with selected recombinant mutants indicates that the immunoreactivity and antigenicity of this bacterial protein can at least be attenuated while preserving fibrinolytic activity and fibrin specificity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anderson HV, Willerson JT. Thrombolysis in acute myocardial infarction. N Engl J Med 1993;329:703–709.
Verstraete M. Use of thrombolytic drugs in non-coronary disorders. Drugs 1994;38:801–821.
Verstraete M. Thrombolysis for arterial conditions other than myocardial infarction. Cor Art Dis 1994;5:317–321.
Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991;78:3114–3124.
Lincoff AM, Topol EJ. Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute MI? Circulation 1993;88:1361–1374.
Collen D. Is there an optimal thrombolytic regimen? Cor Art Dis 1994;5:287–291.
Much H. Über eine Vorstufe des Fibrinfermentes in Kulturen von Staphylokokkus aureus. Biochemische Zeitschrift 1908;14:143–155.
Schlott B, Hartmann M, Gÿhrs KH, et al. High yield production and purification of recombinant staphylokinase for thrombolytic therapy. Biotechnology 1994;12:185–189.
Collen D, Lijnen HR. Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential? Blood 1994;84:680–686.
Vanderschueren SMF, Lijnen HR, Collen D. Properties of staphylokinase and its potential as a thrombolytic agent. Fibrinolysis 1995;9(Suppl 1):87–90.
Collen D, De Cock F, Van Linthout J, Declerck PJ, Lijnen HR, Stassen JM. Comparative thrombolytic and immunogenic properties of staphylokinase and streptokinase. Fibrinolysis 1992;6:232–242.
Collen D, De Cock F, Stassen JM. Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons. Circulation 1993;87:996–1006.
Collen D, Van de Werf F. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation 1993;87:1850–1853.
Vanderschueren S, Collen D, Van de Werf F. Coronary reperfusion in patients with an acute myocardial infarction following intravenous administration of recombinant staphylokinase. J Am Coll Cardiol 1994;00:315A(abstr 928-106).
Collen DC, Gold HK. New developments in thrombolytic therapy. Thromb Res 1990;00(Suppl X):105–131.
Vanderschueren S, Barrios L, Kerdsinchai P, et al. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995;92:2044–2049.
Purvis JA. Novel and innovative dosing regimens in thrombolytic therapy for acute myocardial infarction. J Thromb Thrombolysis 1995;1:145–151.
Agnelli G. Rationale for bolus rt-PA therapy to improve efficacy and safety. Chest 1990;97:161S-167S.
Vanderschueren S, Collen D, Van de Werf F. A pilot study on bolus administration of recombinant staphylokinase for coronary artery thrombolysis. Thromb Haemostas (in press).
Vanderschueren S, Stockx L, Wilms G, Verhaeghe R, Lacroix H, Vermylen J, Collen D. Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase. Circulation 1995;92:2050–2057.
Vanderschueren SMF, Stassen JM, Collen D. On the immunogenicity of recombinant staphylokinase in patients and in animal models. Thromb Haemostas 1994;72:297–301.
Declerck PJ, Vanderschueren S, Billiet J, Moreau H, Collen D. Prevalence and induction of circulating antibodies against recombinant staphylokinase. Thromb Haemost 1994;71:129–133.
Collen D, Bernaerts R, Declerck P, et al. Recombinant staphylokinase variants with altered immunoreactivity. I. Construction and characterization. Circulation, in press.
Collen D, Moreau H, Stockx L, Vanderschueren S. Recombinant staphylokinase variants with altered immunoreactivity. II. Thrombolytic properties and antibody induction. Circulation, in press.
Vanderschueren S, Stassen JM, Collen D. Comparative antigenicity of wild-type staphylokinase (SakSTAR) and a selected mutant (SakSTAR.M38) in a baboon thrombolysis model. J Cardiovasc Pharm, in press.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vanderschueren, S., Collen, D. & Van de Werf, F. Current clinical experience with staphylokinase in arterial thrombosis. J Thromb Thrombol 3, 297–300 (1996). https://doi.org/10.1007/BF00133072
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00133072